Enliven reports 2023 net loss $71.6M; cash $253M; ELVN-001 data due Q2 2024

Enliven Therapeutics, Inc.

Net loss of $71.6M for full year 2023, up from $37.7M in 2022; R&D spend $64.6M.
Cash, cash equivalents and marketable securities $253.1M; expected runway into early 2026.
Phase 1a ELVN-001 proof-of-concept data expected Q2 2024 (n>20 patients at efficacious dose).
ELVN-002 IND cleared for combination with trastuzumab in HER2+ cancers; first patient dosing by mid-2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Enliven Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss of $19.4 million for the fourth quarter of 2023.

Period: the fourth quarter and full year ended December 31, 2023
Net income: net loss of $19.4 million for the fourth quarter of 2023
Result: reported results

Exact text from the filing

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the fourth quarter and full year ended December 31, 2023

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-031482

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.